The short answer
Ask for the drug’s full name and its physical form: for example, a tablet or an injection. Find out whether FDA approved the proposed product, or whether someone will prepare it to order, called compounding. A doctor’s license does not establish the medicine’s approval status.
Amino acids join together to form proteins. A short chain of those building blocks is called a peptide.
The term describes chemistry; it does not establish a product’s legal or safety status, as of September 2026.
Ask which product is proposed
Write down the generic name and any brand name the prescriber gives. Also ask what form is proposed, such as a shot or tablet. The generic name identifies the medicine’s active ingredient, the part intended to do the work.
The Food and Drug Administration, abbreviated FDA, reviews medicines at the federal level.
In the September 2026 check, FDA-approved medicines included semaglutide (Ozempic, Wegovy, Rybelsus), as well as products with tirzepatide (Mounjaro, Zepbound).
Approval covers a defined drug product for a specified use. The phrase peptide therapy cannot carry that approval over to another product.
Ask what the proposed product is approved for and how the prescriber’s plan relates to that use. Keep the answer with the exact name, rather than relying on a general claim about a family of medicines.
The November 3, 2026 check found no generic for either semaglutide or tirzepatide that had approval allowing US sales.
A medicine prepared to order is not an approved generic. In the November 3, 2026 guidance check, describing it as a generic was among the claims FDA called false or misleading.
If the medicine is compounded
A compounder makes a drug to order. That may be a pharmacist, a doctor, or a facility registered for this work. The result is a prepared medicine, rather than a factory’s finished approved drug.
For compounded drugs, the September 2026 rules did not grant FDA approval. Before marketing, FDA has not reviewed that preparation’s quality, safety, or ability to work.
A person may need a made-to-order drug when no approved product meets that medical need.
Ask what need the change addresses for you, who will make the medicine, and why an approved option would not meet that need. An answer about the product’s lower price does not answer those questions.
The September 2026 rules limited an ordinary pharmacy’s repeated preparation of medicines that are essentially copies of drugs already available. Ask why the medicine offered to you would be different from the approved product.
To avoid being treated as a copy, the change must make a real, significant difference for the person named on the prescription. The prescriber must make that judgment. A lower bill alone cannot supply that difference.
One example is a dye allergy: leaving that dye out can address a need the ready-made medicine cannot meet. Ask whether any proposed change matters in your case.
FDA’s September 2026 records did not place semaglutide injection or tirzepatide on its national shortage list.
An empty shelf does not settle whether a national shortage has been declared.
Read registration and research claims carefully
A National Drug Code is a product’s entry number in a drug directory. Having one, or being registered with FDA, did not prove approval in the September 2026 rules.
Ask for the approval record that matches the actual product. A code, badge, or medicine name in an online government directory does not establish approval.
BPC-157 and CJC-1295 are among the ingredients in FDA’s withdrawn-request table, on the page marked current April 22, 2026. The requests had asked FDA to allow those ingredients in medicines prepared to order.
Taking back a request does not give an ingredient FDA approval.
A draft policy from HHS was published October 30, 2026. The initials stand for the Department of Health and Human Services. It addresses six peptides: semax, BPC-157 and KPV, along with TB-500, MOTS-c and epitalon. For an individual patient with a prescription, it describes conditions under which the department does not intend to act against state-licensed physicians or pharmacies that compound one of them. The draft applies to a preparation with one ingredient, and excludes blends.
It leaves 503B outsourcing facilities outside this policy. Those larger facilities prepare batches for hospitals or clinics.
The official 503A bulks list has not gained any of these six peptides. That is FDA’s list of additional raw ingredients permitted for this kind of compounding. This draft states HHS’s plans; it does not force the agency to follow them. It gives these medicines no FDA approval. Ask the prescriber how the proposed preparation meets its conditions.
FDA’s page does not say when each request was taken back. Its safety warnings remain beside the ingredients.
FDA’s concerns include an immune reaction to an injected peptide, unwanted material in the preparation, and too little human safety information to know the risks. These concerns need an answer about the exact medicine and how it would be used.
During 2026, FDA letters challenged sellers whose research labels sat beside claims aimed at human use. The agency called the cited products unapproved drugs despite those labels.
Approval for use in people cannot be read into the words research use only. An online research label cannot replace medical assessment or a prescription.